News >

FDA Grants Priority Review to Frontline Atezolizumab for Advanced PD-L1-High NSCLC

Gina Columbus
Published: Wednesday, Feb 19, 2020

Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development of Genentech (Roche)

Levi Garraway, MD, PhD

The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for single-agent atezolizumab (Tecentriq) as a frontline treatment for patients with advanced nonsquamous or squamous non–small cell lung cancer (NSCLC) without EGFR or ALK mutations who have high PD-L1 expression on tumor cells or tumor-infiltrating immune cells, defined as TC3/IC3 wild-type (WT).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication